Plasma Metabolomics for Discovery of Early Metabolic Markers of Prostate Cancer Based on Ultra-High-Performance Liquid Chromatography-High Resolution Mass Spectrometry.
LC-MS
biomarkers
metabolomics
multivariate analysis
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Jun 2021
23 Jun 2021
Historique:
received:
26
03
2021
revised:
16
06
2021
accepted:
18
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
The prevention and early screening of PCa is highly dependent on the identification of new biomarkers. In this study, we investigated whether plasma metabolic profiles from healthy males provide novel early biomarkers associated with future risk of PCa. Using the Orthogonal partial least squares discriminant analysis (OPLS-DA) discriminated PCa cases from controls, with a median area under the receiver operating characteristic curve (AU-ROC) of 0.92 using a 1000-time repeated random sub-sampling validation. Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) identified the top 10 most important metabolites ( Our results support the dysregulation of amino acids and sphingolipid metabolism during the development of PCa. After validation in an independent cohort, these signatures may promote the development of new prevention and screening strategies to identify males at future risk of PCa.
Sections du résumé
BACKGROUND
BACKGROUND
The prevention and early screening of PCa is highly dependent on the identification of new biomarkers. In this study, we investigated whether plasma metabolic profiles from healthy males provide novel early biomarkers associated with future risk of PCa.
METHODS
METHODS
Using the
RESULTS
RESULTS
Orthogonal partial least squares discriminant analysis (OPLS-DA) discriminated PCa cases from controls, with a median area under the receiver operating characteristic curve (AU-ROC) of 0.92 using a 1000-time repeated random sub-sampling validation. Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) identified the top 10 most important metabolites (
CONCLUSION
CONCLUSIONS
Our results support the dysregulation of amino acids and sphingolipid metabolism during the development of PCa. After validation in an independent cohort, these signatures may promote the development of new prevention and screening strategies to identify males at future risk of PCa.
Identifiants
pubmed: 34201735
pii: cancers13133140
doi: 10.3390/cancers13133140
pmc: PMC8268247
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Sci Rep. 2020 Jul 2;10(1):10926
pubmed: 32616821
Health Technol Assess. 2015 Oct;19(87):i-xxxi, 1-191
pubmed: 26507078
Br J Pharmacol. 2008 Mar;153 Suppl 1:S200-15
pubmed: 17965751
Arch Intern Med. 2004 Nov 22;164(21):2335-42
pubmed: 15557412
PLoS One. 2015 Aug 14;10(8):e0135437
pubmed: 26274920
Metabolites. 2021 Mar 19;11(3):
pubmed: 33808897
Eur Urol Oncol. 2019 Feb;2(1):28-36
pubmed: 30929843
Int J Cancer. 2015 Nov 1;137(9):2124-32
pubmed: 25904191
BMC Urol. 2015 Oct 01;15:99
pubmed: 26429735
Exp Biol Med (Maywood). 2019 Oct;244(13):1053-1061
pubmed: 31573840
Nat Commun. 2019 Sep 25;10(1):4358
pubmed: 31554818
Metabolomics. 2017;13(5):52
pubmed: 28804274
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):
pubmed: 29229664
Clin Breast Cancer. 2018 Aug;18(4):e659-e669
pubmed: 29306659
Anticancer Res. 2019 Jan;39(1):41-56
pubmed: 30591439
Cell Cycle. 2010 Oct 1;9(19):3884-6
pubmed: 20948290
J Clin Oncol. 2011 Jun 10;29(17):2391-6
pubmed: 21537050
BMC Bioinformatics. 2011 Jun 22;12:253
pubmed: 21693065
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):303-309
pubmed: 29684520
Biol Pharm Bull. 2004 Apr;27(4):475-9
pubmed: 15056850
Talanta. 2018 Aug 1;185:483-490
pubmed: 29759231
Theranostics. 2017 Aug 23;7(16):3824-3841
pubmed: 29109780
Nature. 2009 Feb 12;457(7231):910-4
pubmed: 19212411
Mol Biosyst. 2015 Jan;11(1):13-9
pubmed: 25382277
Diagnostics (Basel). 2020 Aug 31;10(9):
pubmed: 32878288
Prostate Cancer Prostatic Dis. 2017 Mar;20(1):12-19
pubmed: 27922627
Urol Oncol. 2011 Jul-Aug;29(4):436-45
pubmed: 19926313
PLoS One. 2011;6(6):e21103
pubmed: 21698256
Diagnostics (Basel). 2020 Jan 19;10(1):
pubmed: 31963920
Future Sci OA. 2015 Dec 17;2(1):FSO72
pubmed: 28031932
Nat Genet. 2014 Oct;46(10):1103-9
pubmed: 25217961
J Natl Cancer Inst. 2003 Jun 18;95(12):868-78
pubmed: 12813170
Mol Cancer Res. 2021 Mar;19(3):475-484
pubmed: 33168599
Expert Rev Mol Diagn. 2015;15(9):1211-24
pubmed: 26174441
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
J Biol Chem. 2014 Sep 5;289(36):25010-20
pubmed: 25063813
Metabolomics. 2021 Mar 11;17(3):32
pubmed: 33704614
Front Genet. 2021 Mar 26;12:652747
pubmed: 33841508
Sci Rep. 2016 Feb 11;6:20984
pubmed: 26865432
Am J Clin Exp Urol. 2021 Apr 15;9(2):189-193
pubmed: 34079852
Br J Cancer. 2016 Oct 25;115(9):1087-1095
pubmed: 27673363
Nat Rev Cancer. 2004 Aug;4(8):604-16
pubmed: 15286740
Anal Chim Acta. 2021 May 8;1158:338381
pubmed: 33863412
J Exp Clin Cancer Res. 2019 Nov 12;38(1):464
pubmed: 31718684
Mediators Inflamm. 2017;2017:4806541
pubmed: 29269995
Adv Exp Med Biol. 2018;1112:293-307
pubmed: 30637705
J Cancer. 2010 Oct 06;1:150-77
pubmed: 20975847
Carcinogenesis. 2013 Oct;34(10):2281-5
pubmed: 23698636
J Nutr. 2016 Aug;146(8):1514-20
pubmed: 27385764
Biochim Biophys Acta. 2016 Oct;1863(10):2422-35
pubmed: 26828774
EJIFCC. 2015 Mar 10;26(2):92-104
pubmed: 27683485
Nat Protoc. 2011 Sep 08;6(10):1483-99
pubmed: 21959233
Nat Rev Cancer. 2018 Jan;18(1):33-50
pubmed: 29147025
Gigascience. 2013 Oct 16;2(1):13
pubmed: 24131531
Genome Med. 2016 Mar 31;8(1):34
pubmed: 27036109
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMC Bioinformatics. 2007 Jul 02;8:234
pubmed: 17605789
Nutr Metab Cardiovasc Dis. 2021 Jun 7;31(6):1645-1652
pubmed: 33895079
Redox Biol. 2020 Jan;29:101380
pubmed: 31926618
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Control Clin Trials. 1998 Aug;19(4):336-51
pubmed: 9683310
Cancers (Basel). 2021 Apr 06;13(7):
pubmed: 33917317
Metabolomics. 2012 Jun;8(Suppl 1):3-16
pubmed: 22593721
Curr Protoc Bioinformatics. 2019 Dec;68(1):e86
pubmed: 31756036
BMC Med. 2020 Jul 23;18(1):187
pubmed: 32698845
Metabolites. 2019 Mar 08;9(3):
pubmed: 30857149
J Natl Cancer Inst. 2002 Jul 3;94(13):981-90
pubmed: 12096083